Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer

Rujuta Saksena, Serena T WongThe Cancer Institute of New Jersey, New Brunswick, NJ, USAAbstract: The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its dysregulation creates an environment that promote...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saksena R, Wong ST
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0b912949152243b5b0031d7cb067a685
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0b912949152243b5b0031d7cb067a685
record_format	dspace
spelling	oai:doaj.org-article:0b912949152243b5b0031d7cb067a6852021-12-02T02:41:16ZClinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer1179-1314https://doaj.org/article/0b912949152243b5b0031d7cb067a6852013-05-01T00:00:00Zhttp://www.dovepress.com/clinical-evidence-of-the-efficacy-of-everolimus-and-its-potential-in-t-a13086https://doaj.org/toc/1179-1314Rujuta Saksena, Serena T WongThe Cancer Institute of New Jersey, New Brunswick, NJ, USAAbstract: The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its dysregulation creates an environment that promotes tumorigenesis as well as resistance to therapy. The mTOR inhibitor everolimus has emerged as a promising agent in the treatment of breast cancer and was recently approved in combination with exemestane for advanced hormone receptor–positive disease after progression on a nonsteroidal aromatase inhibitor. Everolimus may also be effective in combination with cytotoxic and human epidermal growth factor receptor-2-directed therapies for the treatment of other subtypes of breast cancer. This paper highlights preclinical and clinical data that have emerged on the role of mTOR inhibition in breast cancer. Although generally well tolerated, everolimus carries a unique side effect profile of which both patients and providers should be made aware. Recommendations related to the administration of everolimus in the clinical setting are also discussed.Keywords: everolimus, breast cancer, mTOR inhibitionSaksena RWong STDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 27-35 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Saksena R Wong ST Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
description	Rujuta Saksena, Serena T WongThe Cancer Institute of New Jersey, New Brunswick, NJ, USAAbstract: The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its dysregulation creates an environment that promotes tumorigenesis as well as resistance to therapy. The mTOR inhibitor everolimus has emerged as a promising agent in the treatment of breast cancer and was recently approved in combination with exemestane for advanced hormone receptor–positive disease after progression on a nonsteroidal aromatase inhibitor. Everolimus may also be effective in combination with cytotoxic and human epidermal growth factor receptor-2-directed therapies for the treatment of other subtypes of breast cancer. This paper highlights preclinical and clinical data that have emerged on the role of mTOR inhibition in breast cancer. Although generally well tolerated, everolimus carries a unique side effect profile of which both patients and providers should be made aware. Recommendations related to the administration of everolimus in the clinical setting are also discussed.Keywords: everolimus, breast cancer, mTOR inhibition
format	article
author	Saksena R Wong ST
author_facet	Saksena R Wong ST
author_sort	Saksena R
title	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
title_short	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
title_full	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
title_fullStr	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
title_full_unstemmed	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
title_sort	clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/0b912949152243b5b0031d7cb067a685
work_keys_str_mv	AT saksenar clinicalevidenceoftheefficacyofeverolimusanditspotentialinthetreatmentofbreastcancer AT wongst clinicalevidenceoftheefficacyofeverolimusanditspotentialinthetreatmentofbreastcancer
_version_	1718402267777859584

Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer

Ejemplares similares